None
Quote | ImmunoPrecise Antibodies Ltd. (OTCMKTS:IPATF)
Last: | $18.70 |
---|---|
Change Percent: | 0.43% |
Open: | $18.8 |
Close: | $18.70 |
High: | $20.254 |
Low: | $17.7 |
Volume: | 63,314 |
Last Trade Date Time: | 12/29/2020 04:54:56 pm |
News | ImmunoPrecise Antibodies Ltd. (OTCMKTS:IPATF)
ImmunoPrecise Antibodies (NASDAQ:IPA) said its antibody cocktail PolyTope TATX-03 showed strong neutralizing activity against Omicron subvariant BA.2 in lab test. In-vitro data showed that the BA.2 pseudovirus was neutralized with a potency comparable to the previously analyzed Omicron B...
ImmunoPrecise Antibodies (IPATF) has announced the identification of antibody 23-H7, which preclinical data obtained to date indicates provides strong, protective anti-viral effects in SARS-CoV-2 (COVID-19) infected Syrian hamsters via an uncommon mechanism of action.In vivo efficac...
Message Board Posts | ImmunoPrecise Antibodies Ltd. (OTCMKTS:IPATF)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
ImmunoPrecise Antibodies Ltd. Company Name:
IPATF Stock Symbol:
OTCMKTS Market:
ImmunoPrecise Antibodies to Begin Trading on Nasdaq Stock Exchange Canada NewsWire VICTORIA, BC , Dec. 23, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV: IPA) (Nasdaq Global Markets: IPA), a leader in full-service, therapeu...
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter of 2021 Fiscal Year Canada NewsWire Record Quarterly Revenue of $4,754,545 and Adjusted EBITDA of $795,159 Announced Strategic Partnership ...
ImmunoPrecise and LiteVax Advance SARS-CoV-2 Vaccine Candidate VICTORIA, BC , Dec. 14, 2020 /PRNewswire/ - IMMUNOPRECISE ANTIBODIES LTD. ("IPA") (TSXV: IPA) (IPATD: IPA) (FSE: TQB), a leader in full-service, therapeutic antibody discovery and development and LiteVax...